Search

Search Results
Results 14171 - 14180 of 17235 for Active treatment
  • Drug - 26 Sep 2025
    Consumer Medicine Information (CMI) about Skyrizi intended for persons living in Australia.
  • News - 25 Sep 2025
    A British led study published by The BMJ today provides detailed data on the pattern and severity of traumatic injuries and medical conditions seen by international healthcare workers deployed to Gaza...
  • News - 24 Sep 2025
    Changes in vision are often a common sign of aging. If you sit in a dimly lit restaurant with anyone over the age of 60, you'll likely hear the person say, "Hold on - let me pull out my cell phone. I...
  • News - 24 Sep 2025
    Obstetricians have long advised their pregnant patients that Tylenol is the safest option to reduce fever or pain. President Donald Trump stood before a national audience on Sept. 22 and contradicted...
  • Drug - 24 Sep 2025
    Consumer Medicine Information (CMI) about Abiraterone Viatris intended for persons living in Australia.
  • News - 23 Sep 2025
    Backed by the combined expertise of three USC schools, scientists are developing a new drug aimed at a previously unexplored biological target in Alzheimer's disease, aided by an $8 million grant from...
  • Drug - 23 Sep 2025
    Consumer Medicine Information (CMI) about Aspalgin intended for persons living in Australia.
  • Drug - 23 Sep 2025
    Consumer Medicine Information (CMI) about Brimica Genuair inhaler intended for persons living in Australia.
  • Drug - 23 Sep 2025
    Consumer Medicine Information (CMI) about Bretaris Genuair inhaler intended for persons living in Australia.
  • Drug - 19 Sep 2025
    Consumer Medicine Information (CMI) about Inlyta intended for persons living in Australia.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.